A 26-week Randomised, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone with Concurrent Insulin Therapy and/or a Sulphonylurea in Type 2 Diabetic Patients with Chronic Renal Failure (Not on Dialysis).
Diabetes Mellitus, Type 2
Phase 3
A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
February 2015